Results 51 to 60 of about 1,064,547 (319)
Pediatric Blood &Cancer, EarlyView.ABSTRACT Introduction The use of herbal medical preparation (HMP) is rising among pediatric oncology patients, often to manage treatment‐related symptoms. Their effectiveness remains uncertain, and the risk of herb–drug interactions is underestimated.
Orianne Mahot +6 more
wiley +1 more source
, 1999 Therapeutics Letter 31 considers the importance of making unpublished clinical trial data available in the context of the approval of celecoxib. Conclusions: In this case, the only information available to help the clinician decide whether to prescribe ...
Therapeutics Initiative (University of British Columbia)
core
Communications BiologyXRN1 (5’-3’ exoribonuclease 1) degrades RNA from the 5′ → 3′ direction and utilizes both single- and double-stranded RNA as substrates. XRN1 plays a critical role in mRNA turnover as well as regulating the cellular response to viral infection.
Gordon J. Lockbaum +21 more
doaj +1 more source
Personalized Zebrafish Models for Fusion‐Positive Pediatric Sarcomas
Pediatric Blood &Cancer, EarlyView.ABSTRACT Clinical sequencing efforts have revolutionized our approaches to categorizing pediatric cancers in real time. This has dramatically improved our ability to profile pediatric tumors, identify actionable vulnerabilities, and influence clinical care.
Lisa H. Hall +2 more
wiley +1 more source
, 2001 Therapeutics Letter 39 adds new evidence to information previously published about NSAIDs in Therapeutics Letters 4 and Letter 17. It also responds to our commitment in Therapeutics Letter 31 to report on celecoxib when published trials became available.
Therapeutics Initiative (University of British Columbia)
core
, 2021 Therapeutics Letter 131 considers the harms and potential benefits of tramadol. Conclusions: Compared with acetaminophen, NSAIDs or other opioids, tramadol has no therapeutic advantage but some disadvantages.
Therapeutics Initiative (University of British Columbia)
core
The Role of “Adult‐Onset” Cancer Predisposition Genes in Pediatric Cancer: A Comprehensive Review
Pediatric Blood &Cancer, EarlyView.ABSTRACT Current literature estimates that 10% of pediatric cancers are caused by pathogenic or likely pathogenic (P/LP) germline variants in cancer predisposition genes (CPGs). Variants in CPGs thought to increase cancer risk exclusively during adulthood are referred to as “adult‐onset” CPGs (aoCPGs).
Maria Rozo +5 more
wiley +1 more source
Scientific ReportsMultiple sclerosis (MS) is a chronic neurological disease characterized by inflammatory demyelination that disrupts neuronal transmission resulting in neurodegeneration progressive disability.
Michael M. Poon +13 more
doaj +1 more source
Early Impact of Childhood Opportunity on Neurocognitive Outcomes in Sickle Cell Disease
Pediatric Blood &Cancer, EarlyView.ABSTRACT Introduction Neurocognitive impairment is a well‐recognized complication of sickle cell disease (SCD) that begins early in childhood and persists across development. While cerebrovascular injury contributes substantially to risk, neurocognitive deficits are also observed in children without overt or silent cerebral infarctions, suggesting ...
Julia E. LaMotte +5 more
wiley +1 more source
, 2012 Therapeutics Letter 85 presents selected direct quotes published in recent issues of Prescrire International. Topics covered include aliskiren, drugs for Alzheimer's disease, escitalopram, gabapentin, pregabalin, migraine headaches, and varenicline ...
Therapeutics Initiative (University of British Columbia)
core